Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom China France

After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation.The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets.The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1 receptor agonists, with no unexpected safety signals during the study.View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-1-receptor-agonist-gzr18-tablet-in-healthy-participants-demonstrating-4-16-weight-reduction-in-two-weeks-302302394.html